Head and neck cancer study for older adults
Part of Cancer clinical trials.
This trial tests a combination of chemotherapy and immunotherapy followed by radiation for older adults with head and neck cancer. It aims to see if this approach is safe and effective for people aged 65 and older.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 65 years or older.
- You must have a type of head and neck cancer called squamous cell carcinoma, at a stage between IB and IVA.
- You must be in generally good health, able to care for yourself (ECOG score 0–2), and have adequate organ function.
- You cannot have already received chemotherapy or immunotherapy for this cancer.
- You must be evaluated by both a medical oncologist and a radiation oncologist.
- If you join the experimental group, you must be able to receive chemoimmunotherapy followed by radiation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two chemotherapy drugs (carboplatin and paclitaxel) plus a targeted therapy (cetuximab) for people with advanced head and neck cancer that has gotten worse after treatment with pembrolizumab (with or without initial chemotherapy). The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
This trial studies how to predict side effects (toxicity) in older adults (70+) with advanced head and neck cancer. It tests standard treatments like radiation, chemoradiation, or radiation with cetuximab and aims to help doctors tailor care to reduce harm.
This Phase 2 study tests pembrolizumab (an immunotherapy medicine) together with induction chemotherapy before the main cancer treatment for stage III/IVA head and neck squamous cell cancer. It aims to improve how well the tumor responds and how long people can stay controlled.
This trial tests a new way to give chemotherapy (pulsed doses) together with pembrolizumab (an immunotherapy) for people with head and neck cancer that has come back or spread and cannot be cured with local treatments. The goal is to see if this combination works better than standard approaches.
This trial tests whether adding pembrolizumab (an immunotherapy drug) to standard chemotherapy before surgery can help people with advanced head and neck cancer. It aims to see if the combination is more effective than chemotherapy alone.
This trial tests whether adding an immunotherapy drug (toripalimab) with or without another targeted drug (cetuximab) to standard chemotherapy before surgery can improve outcomes for people with advanced head and neck squamous cell carcinoma that can be removed with surgery.
Hear when a new Head and Neck Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.